Dyslipidemia in AIDS patients on highly active antiretroviral therapy
Highly active antiretroviral therapy (HAART) reduces AIDS-related morbidity and mortality, however it has been associated with metabolic abnormalities. This study estimated the prevalence of lipid abnormalities and related factors among patients on HAART. A cross-sectional study was conducted on adu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2011-03-01
|
| Series: | Brazilian Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1413867011701611 |
| _version_ | 1818174962483068928 |
|---|---|
| author | Max Weyler Nery, MD, MSc Celina Maria Turchi Martelli, MD, PhD Marília Dalva Turchi, MD, PhD |
| author_facet | Max Weyler Nery, MD, MSc Celina Maria Turchi Martelli, MD, PhD Marília Dalva Turchi, MD, PhD |
| author_sort | Max Weyler Nery, MD, MSc |
| collection | DOAJ |
| description | Highly active antiretroviral therapy (HAART) reduces AIDS-related morbidity and mortality, however it has been associated with metabolic abnormalities. This study estimated the prevalence of lipid abnormalities and related factors among patients on HAART. A cross-sectional study was conducted on adult patients, in central Brazil. Patients were interviewed, and blood obtained for lipids measurement. Dyslipidemia was defined as total cholesterol (TC) ≥ 240 mg/dL, low-density lipoprotein (LDL) ≥ 160 mg/dL, triglycerides (TG) > 200 and/or high-density lipoprotein (HDL) < 40 mg/dL. Multiple logistic regression analyses were performed (SPSS 13.0). One hundred and thirteen patients were recruited. Mean age was 39.3 years; 68.1% were males; 50.4% were on nucleoside reverse transcriptase inhibitors (NRTI) in combination with non-nucleoside reverse transcriptase inhibitors (NNRTI), while 42.5% were on NRTI in combination with protease inhibitors (PIs). The prevalence of dyslipidemia was 66.7%. Low HDL was the most frequent abnormality (53.5%), followed by high TG (36.1%). Patients on a PI regimen had a 5.2-fold higher risk (95% CI: 1.8-14.8) of dyslipidemia, even after adjusting for sex, age, and duration of HIV infection/AIDS. The study discloses a high prevalence rate of dyslipidemia and points out a need for intervention programs to reduce future cardiovascular events in patients, on HAART. Keywords: prevalence, dyslipidemia, HIV, AIDS, HAART |
| first_indexed | 2024-12-11T19:52:44Z |
| format | Article |
| id | doaj.art-60edeed9e5fe488a829fbc23a4314506 |
| institution | Directory Open Access Journal |
| issn | 1413-8670 |
| language | English |
| last_indexed | 2024-12-11T19:52:44Z |
| publishDate | 2011-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brazilian Journal of Infectious Diseases |
| spelling | doaj.art-60edeed9e5fe488a829fbc23a43145062022-12-22T00:52:44ZengElsevierBrazilian Journal of Infectious Diseases1413-86702011-03-01152151155Dyslipidemia in AIDS patients on highly active antiretroviral therapyMax Weyler Nery, MD, MSc0Celina Maria Turchi Martelli, MD, PhD1Marília Dalva Turchi, MD, PhD2Departamento de Medicina da Pontifícia, Universidade Católica de Goiás, Brazil; Correspondence to: Departamento de Medicina da Pontifícia, Universidade Católica de Goiás, Av. Universitária, 1440, Setor Universitário, Área IV, CEP: 74.605-010 Goiânia, Goiás, Brasil Phone: (62) 3250 4000, 3250 4014, Fax: (62) 3250 4024.Instituto de Patologia Tropical e Saúde, Pública da Universidade Federal de Goiás, BrazilInstituto de Patologia Tropical e Saúde, Pública da Universidade Federal de Goiás, BrazilHighly active antiretroviral therapy (HAART) reduces AIDS-related morbidity and mortality, however it has been associated with metabolic abnormalities. This study estimated the prevalence of lipid abnormalities and related factors among patients on HAART. A cross-sectional study was conducted on adult patients, in central Brazil. Patients were interviewed, and blood obtained for lipids measurement. Dyslipidemia was defined as total cholesterol (TC) ≥ 240 mg/dL, low-density lipoprotein (LDL) ≥ 160 mg/dL, triglycerides (TG) > 200 and/or high-density lipoprotein (HDL) < 40 mg/dL. Multiple logistic regression analyses were performed (SPSS 13.0). One hundred and thirteen patients were recruited. Mean age was 39.3 years; 68.1% were males; 50.4% were on nucleoside reverse transcriptase inhibitors (NRTI) in combination with non-nucleoside reverse transcriptase inhibitors (NNRTI), while 42.5% were on NRTI in combination with protease inhibitors (PIs). The prevalence of dyslipidemia was 66.7%. Low HDL was the most frequent abnormality (53.5%), followed by high TG (36.1%). Patients on a PI regimen had a 5.2-fold higher risk (95% CI: 1.8-14.8) of dyslipidemia, even after adjusting for sex, age, and duration of HIV infection/AIDS. The study discloses a high prevalence rate of dyslipidemia and points out a need for intervention programs to reduce future cardiovascular events in patients, on HAART. Keywords: prevalence, dyslipidemia, HIV, AIDS, HAARThttp://www.sciencedirect.com/science/article/pii/S1413867011701611 |
| spellingShingle | Max Weyler Nery, MD, MSc Celina Maria Turchi Martelli, MD, PhD Marília Dalva Turchi, MD, PhD Dyslipidemia in AIDS patients on highly active antiretroviral therapy Brazilian Journal of Infectious Diseases |
| title | Dyslipidemia in AIDS patients on highly active antiretroviral therapy |
| title_full | Dyslipidemia in AIDS patients on highly active antiretroviral therapy |
| title_fullStr | Dyslipidemia in AIDS patients on highly active antiretroviral therapy |
| title_full_unstemmed | Dyslipidemia in AIDS patients on highly active antiretroviral therapy |
| title_short | Dyslipidemia in AIDS patients on highly active antiretroviral therapy |
| title_sort | dyslipidemia in aids patients on highly active antiretroviral therapy |
| url | http://www.sciencedirect.com/science/article/pii/S1413867011701611 |
| work_keys_str_mv | AT maxweylernerymdmsc dyslipidemiainaidspatientsonhighlyactiveantiretroviraltherapy AT celinamariaturchimartellimdphd dyslipidemiainaidspatientsonhighlyactiveantiretroviraltherapy AT mariliadalvaturchimdphd dyslipidemiainaidspatientsonhighlyactiveantiretroviraltherapy |